Shira N. Dinner, MD [slides]- Therapies for Older Adult ALL

The presentation delved into groundbreaking treatment modalities for older adults with acute lymphoblastic leukemia (ALL), spotlighting the utilization of innovative therapies like blinatumomab and inotuzumab. Shira N. Dinner, MD discussed the challenges associated with historical poor outcomes in this population.

Category:
Description:

Shira N. Dinner, MD- Robert H Lurie Cancer Center

Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches.

REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US - Online content available - https://aml-allus2023.md-education.com/register/
AML-ALL EU - Registration open - https://aml-alleu2023.md-education.com/register/
MPN-MDS EU - registration open - https://mpn-mdseu2023.md-education.com/register/

Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to younger patients. The presentation covered studies involving various treatment strategies, including the use of venetoclax, blinatumomab, inotuzumab, and combination therapies.

One study investigated the combination of mini chemotherapy regimen CBD (cyclophosphamide, vincristine, dexamethasone) with inotuzumab and blinatumomab. While showing promising results, the presentation raised concerns about secondary myeloid neoplasms and questioned whether chemotherapy could be further reduced in this population.